1,309 reports of this reaction
2.2% of all RABEPRAZOLE SODIUM reports
#6 most reported adverse reaction
END STAGE RENAL DISEASE is the #6 most commonly reported adverse reaction for RABEPRAZOLE SODIUM, manufactured by Waylis Therapeutics LLC. There are 1,309 FDA adverse event reports linking RABEPRAZOLE SODIUM to END STAGE RENAL DISEASE. This represents approximately 2.2% of all 58,263 adverse event reports for this drug.
Patients taking RABEPRAZOLE SODIUM who experience end stage renal disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
END STAGE RENAL DISEASE is a less commonly reported adverse event for RABEPRAZOLE SODIUM, but still significant enough to appear in the safety profile.
In addition to end stage renal disease, the following adverse reactions have been reported for RABEPRAZOLE SODIUM:
The following drugs have also been linked to end stage renal disease in FDA adverse event reports:
END STAGE RENAL DISEASE has been reported as an adverse event in 1,309 FDA reports for RABEPRAZOLE SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
END STAGE RENAL DISEASE accounts for approximately 2.2% of all adverse event reports for RABEPRAZOLE SODIUM, making it a notable side effect.
If you experience end stage renal disease while taking RABEPRAZOLE SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.